Security key
19188J409
Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP)
CUSIP: 19188J409
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 97
- Total 13F value
- $112
- Share change
- +13
- SEC-reported price per share
- $1.15
- Number of holders
- 2
- Value change
- +$15
- Number of buys
- 1
- Shares outstanding
- 19,232,824
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
2
Top holders
2
COCP full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q2 2026
Cocrystal Pharma, Inc. SEC filings
Cocrystal Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 19188J409
Recent filing periods:
Ownership snapshot
Top reported holders of COCP - Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
OPKO HEALTH, INC.
Disclosed value leader
OPKO HEALTH, INC.
Comparable rows
15/15
Latest evidence
05 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 30%
13D/G row: OPKO HEALTH, INC.
Showing 1-6 of 15 holder rows.
Quick read
OPKO HEALTH, INC. leads the comparable SEC ownership view at 30%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens OPKO HEALTH, INC.'s linked filing trail.
Comparable ownership
Top 5
OPKO HEALTH, INC.
30%
Frost Phillip MD Et al
14%
VANGUARD CAPITAL MANAGEMENT LLC
1.9%
RENAISSANCE TECHNOLOGIES LLC
0.93%
TWO SIGMA INVESTMENTS, LP
0.91%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| OPKO HEALTH, INC. |
13D/G
|
30%
|
$5,977,562
5,692,916 shares
|
$0 | 31 Jul 2026 |
| Frost Phillip MD Et al |
3/4/5
13D/G
Director, 10%+ Owner · Phillip Frost, M.D.
|
14%
from 13D/G
|
$2,985,326
2,764,692 shares
mixed-class rows
|
+$300,212 | 05 Aug 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
1.9%
|
$376,139
358,228 shares
|
— | 30 Jun 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.93%
|
$188,609
179,628 shares
|
— | 30 Jun 2026 |
| TWO SIGMA INVESTMENTS, LP |
13F
Company
|
0.91%
|
$184,148
175,379 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.4%
|
$80,034
76,208 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
97
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
26
Q3 2026 holders
2
Holder diff
-24
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend